Trends in diabetes-related complications in Hong Kong, 2001–2016: a retrospective cohort study

Hongjiang Wu¹, Eric S. H. Lau¹, Aimin Yang¹,², Ronald C. W. Ma¹,²,³, Alice P. S. Kong¹,²,³, Elaine Chow¹, Wing-Yee So¹,², Juliana C. N. Chan¹,²,³ and Andrea O. Y. Luk¹,²,³*

Abstract
Background: Nationwide studies on contemporary trends in incidence of diabetes-related complications in Asia are lacking. We describe trends in incident coronary heart disease (CHD), stroke, heart failure, hyperglycaemic crisis, and lower-extremity amputation (LEA) in people with diabetes in Hong Kong between 2001 and 2016.

Methods: The Hong Kong Diabetes Surveillance Database (HKDSD) is a territory-wide diabetes cohort identified from Hong Kong Hospital Authority electronic medical record system. We identified events of CHD, stroke, heart failure and hyperglycaemic crisis using hospital principal diagnosis codes at discharge and that of LEA using inpatient procedure codes. We used Joinpoint regression analysis to describe incidence trends by age and sex.

Results: Between 2001 and 2016, a total of 390,071 men and 380,007 women aged 20 years or older with diabetes were included in the HKDSD. Event rates of CHD, stroke, heart failure, hyperglycaemic crisis and LEA declined by 69.4% (average annual percent change: −7.6, 95% CI −10.2, −5.0), 70.3% (−8.7, 95% CI −9.8, −7.5), 63.6% (−6.4, 95% CI −8.0, −4.7), 59.1% (−6.6, 95% CI −12.4, −0.44), and 67.5% (−5.8, 95% CI −7.2, −4.4), in men and by 77.5% (−9.9, 95% CI −11.8, −7.9), 74.5% (−9.0, 95% CI −9.6, −8.4), 65.8% (−7.0, 95% CI −8.0, −6.0), 81.7% (−8.5, 95% CI −10.5, −6.5), and 72.7% (−9.1, 95% CI −12.2, −5.8) in women, respectively, over a 16-year period in people with diabetes in Hong Kong. Joinpoint analysis identified greater declines in event rates of the five diabetes-related complications in the earlier one-third of study period and slowed down but remained significant until 2016. Event rates decreased for all age groups above 45 years for both sexes. There was no significant change in event rates in the group aged 20–44 years except for decline in hyperglycaemic crisis.

Conclusions: The event rates of diabetes-related complications have declined substantially with no evidence of stabilization or increase in Hong Kong up to 2016. Improvements in outcome were observed for all age subgroups but not in young people with diabetes, calling for urgent action to improve quality of care to prevent complications in young people at risk.

Keywords: Diabetes, Trends, Complications, Coronary heart disease, Stroke, Heart failure, Hyperglycaemic crisis, Lower-extremity amputation

Background
The prevalence of diabetes is increasing worldwide, particularly in Asian countries which contribute over 60% of the global population with diabetes [1]. Uncontrolled diabetes dramatically increases the risk of macrovascular
and microvascular complications including atherosclerotic cardiovascular disease, heart failure, lower extremity amputations (LEA), end-stage kidney disease and blindness, which are major contributors to disability and mortality in people with diabetes [2–4]. Complications from diabetes can be delayed or prevented by intensive regulation of blood glucose and other metabolic risk factors through lifestyle changes and pharmacological intervention [5, 6]. High income countries from Europe and North America reported large reduction in rates of most diabetes complications over a two-decade period since the 1990s although recent surveillance in the United States (U.S.) has identified a rebound in the incidence of LEA and hyperglycaemic crisis and stabilization of cardiovascular and kidney events in the last 5 years. There is a call for re-examination of trends in the incidence of diabetes-related complications given the changing characteristics of people with diabetes including progressively younger age of disease onset but longer living span and increasing rates of obesity especially in young people [7, 8]. On the other hand, recent introduction of sodium-glucose co-transporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists which have been shown to prevent atherosclerotic cardiovascular diseases and hospitalisation for heart failure may affect the trends of some of these complications [9–11].

The establishment of the Hong Kong Hospital Authority (HA) which governs all public hospitals and the majority of government out-patient clinics in 1990 has positively transformed health service delivery in Hong Kong with improved integration of primary, secondary and tertiary care for 7.3 million people currently residing in Hong Kong. The Hong Kong Diabetes Surveillance Database (HKDSD) is a retrospective cohort of people with diabetes identified from the electronic medical record (EMR) system used in the Hong Kong HA and provides population-level statistics on health outcome among people with diabetes. Using the HKDSD, we previously reported a 15-year decline in absolute mortality in people with diabetes and relative mortality comparing people with and without diabetes [12]. Despite this encouraging trend, diabetes-related complications are major causes of morbidity, loss of societal productivity and poor quality of life. Yet, regionally representative trend data are scarce in Asia. In this study, we describe the trends in incidence rates of diabetes-related complications in Hong Kong Chinese with diabetes between 2001 and 2016.

Methods
Study population
The Hong Kong HA is a statutory administrative body formed in 1990, and manages all 43 public hospitals/ institutions, 49 specialist clinics, and 73 general (primary care) out-patient clinics in Hong Kong. In 2000, the HA adopted a territory-wide EMR system to capture demographic information, diagnostic and procedure codes, laboratory results, prescription and consultation records of all people attending public hospitals and clinics through their unique Hong Kong Identity Card number [13]. This EMR system provides a standardized repository of all the clinical data and gives clinicians an integrated, longitudinal and lifelong view of people’s healthcare record. In the period 2015 to 2016, the HA EMR system recorded about 6.2 million attendees in general out-patient clinics, 7.2 million attendees in specialist clinics and 1.1 million inpatient services, covering ~90% of total medical services in Hong Kong [14].

The HKDSD is a population-based cohort of people with diabetes identified from the HA EMR system. Diabetes was ascertained based on one or more of the following qualifying criteria: (1) recording of diagnostic code of diabetes based on International Classification of Diseases, Ninth Revision (ICD-9) code of 250.xx; (2) recording of diagnostic code of diabetes according to the Revised Edition of the International Classification of Primary Care, World Organization of National Colleges, Academies, and Academic Associations of General Practitioners/Family Physicians code T89 or code T90; (3) glycated haemoglobin (HbA1c) ≥ 6.5% (48 mmol/mol) in any one available measurement; (4) fasting plasma glucose ≥ 7.0 mmol/L in any one available measurement; (5) ever prescribed glucose-lowering drugs; or (6) long-term prescription of insulin (≥ 28 days). Women with gestational diabetes were not included in the HKDSD based on the diagnoses occurring 9 months before or 6 months after delivery (ICD-9 code 72-75) or within 9 months of any pregnancy-related encounter (ICD-9 codes 630-676). However, women with subsequent episodes that met the criteria of diabetes occurring outside the context of any obstetric events would be included. This study was approved by the local clinical research ethics committee.

Outcome ascertainment
We included five diabetes-related complications in our study, including coronary heart disease (CHD), stroke, heart failure, hyperglycaemic crisis (including diabetic ketoacidosis and hyperglycaemic hyperosmolar state), and LEA, which are major disease burdens. We identified events of CHD (ICD-9 codes: 410-414), stroke (ICD-9 codes: 430-434, 436-438), heart failure (ICD-9 codes: 428), and hyperglycaemic crisis (ICD-9 codes: 250.1 and 250.2) using hospital principal diagnosis codes at discharge. We identified LEA events using inpatient procedure codes (ICD-9 procedure codes: 84.10-84.19, excluding discharges with a traumatic amputation.
annual incidence rate of diabetes-related complications and the trend estimates. We calculated age-standardized prevalence of statin use in people with diabetes, as statins are effective treatment in primary and secondary prevention of cardiovascular diseases [16, 17]. Additionally, we calculated annual age-standardized prevalence of use of new glucose-lowering drugs including dipeptidyl-peptidase-4 (DPP-4) inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors [18, 19].

We performed two sensitivity analyses. First, we repeated the analysis by excluding people newly included in the HKDSD in each study year from the denominator, to assess the effect of a progressive increase in diabetes detection over time through improved diagnostics and screening efforts on trends in rates of diabetes-related complications. Second, we repeated the analysis excluding 2426 people with type 1 diabetes of onset date between 2002 and 2015, identified using a validated algorithm [20]. Due to restriction of the algorithm, we could not identify people with prevalent type 1 diabetes of onset date before 2002. We performed all analyses using R (version 3.5.3, Vienna, Austria) or Joinpoint Regression Program (version 4.7.0.0; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute). A two-tailed $P$ value less than 0.05 was considered statistically significant.

Results

This study included 390,071 men and 380,007 women with diabetes aged 20 years or older in Hong Kong between 2001 and 2016. The number of men and women living with diabetes in the middle of the year increased by approximately 4.5 and 3.5 times compared to 2001 during this 16-year period, respectively (Additional file 1: Figure S1 and Table S1). Between 2001 and 2016, there was an increase in mean age but a decrease in fasting glucose, HbA1c and low-density lipoprotein (LDL)-cholesterol level among people in the HKDSD (Additional file 1: Table S1). A total of 146,187 CHD events, 127,567 stroke events, 121,499 heart failure events, 5230 hyperglycaemic crisis events and 10,294 LEA events were recorded in the HKDSD. The total event number of the five diabetes-related complications also rose from 2001 to 2016 albeit to a lesser extent, with the greatest relative increase in heart failure in both sexes (Additional file 1: Figure S2).

Men consistently had higher event rates of CHD, stroke, heart failure and LEA than women across all age groups although the difference was less prominent in people aged $\geq$75 years (Fig. 1, Additional file 1: Tables S2 and S3). The event rates of hyperglycaemic crisis were higher in women than men in the earlier part of the study period and reversed after 2011. The event rates of diabetes-related complications increased with increasing age group, with the exception of hyperglycaemic crisis, which was greatest in the youngest age group of 20–44 years in both sexes (Additional file 1: Tables S2 and S3).

Trends in event rates by sex

From 2001 to 2016, the event rates declined significantly by 69.4% for CHD, 70.3% for stroke, 63.6% for heart failure, 59.1% for hyperglycaemic crisis and 67.5% for LEA in men (Fig. 1 and Table 1). The corresponding declines in women was 77.5% for CHD, 74.5% for stroke, 65.8% for heart failure, 81.7% for hyperglycaemic crisis and 72.7%
for LEA (Fig. 1 and Table 2). The point estimates of all the AAPCs for declines in diabetes-related complications were higher in women than men, but generally with overlapping 95% CIs. The greatest AAPC was observed for stroke (−8.7, 95% CI −9.8, −7.5) followed by CHD (−9.9, 95% CI −11.8, −7.9) for men, and for LEA (−9.1, 95% CI −12.2, −5.8) in women. The smallest AAPC was observed for LEA in men (−5.8, 95% CI −7.2, −4.4) and for heart failure in women (−7.0, 95% CI −8.0, −6.0). When stratified by anatomical level, greater declines were observed for minor LEA than major LEA in both sexes (Additional file 1: Table S4). Joinpoint regression analysis showed that the declines in event rates of the five diabetes-related complications were generally more marked in the first 3 to 7 years of the surveillance period and slowed down but were still significant until 2016 for both sexes (Fig. 1, Tables 1 and 2). Sensitivity analysis excluding people newly included in the HKDSD in each year (Additional file 1: Figure S3) or people with incident type 1 diabetes (data are not shown) yielded similar declining trends in rates of diabetes-related complications.

**Trends in event rates by age**

The declining trends in event rates of diabetes-related complications varied by age group. In young men and women aged 20–44 years, event rates for most diabetes-related complications were stable except for a decline in hyperglycaemic crisis in both men (AAPC: −3.9, 95% CI −6.2, −1.5) and women (AAPC: −8.7, 95% CI −10.8, −6.6), and a decline in stroke (AAPC: −4.4, 95% CI −7.5, −1.1) in women (Table 1 and 2). In other age-subgroups, the pattern of decreasing rates of the five diabetes-related complications was generally similar to that in the whole age group. The largest AAPCs for CHD, stroke and heart failure were observed in the age group of 65–74 year in both sexes. The largest AAPCs for LEA were in the age group of ≥75 years in men and 65–74 years in women, and for hyperglycaemic crisis, in the age group of ≥75 years in both sexes (Tables 1 and 2). The differential declines across age groups resulted in a decrease in proportion of people aged 65–74 years contributing to CHD, stroke and heart failure events between 2001 and 2016 (Fig. 2). In 2001, men aged ≥75 years accounted for 21.0% of CHD, 34.4% of stroke and 47.6% of heart failure events, and the proportions increased to 31.8%, 43.7% and 61.9% respectively in 2016. For women, the contribution of the oldest age group to CHD, stroke and heart failure events increased from 37.8%, 46.6% and 83.3% in 2001, to 64.1%, 64.9% and 83.3% in 2016, respectively. For LEA, an increase in proportion of people aged 45–64 years was observed. There was no clear changing pattern in relation to age for hyperglycaemic crisis. The youngest age group of 20–44 years contributed to a larger proportion of hyperglycaemic crisis events compared with contribution to other complications. The details of trends in proportion of the five diabetes-related complications by age group from 2001 to 2016 are shown in Additional file 1: Figures S4–S8.

**Trends in prevalence of statin and use of new glucose-lowering drugs**

In 2001, 11.0% of men and 10.4% of women with diabetes ever used statins (Additional file 1: Table S5). The prevalence of statin use was constant before 2008 and increased dramatically thereafter to 44.5% in men and
Table 1 Joinpoint analysis of trends in age-standardized event rates of diabetes-related complications in men with diabetes

| Complications           | Event rates (per 10,000) | Time period 1 | Time period 2 | Time period 3 |
|------------------------|--------------------------|---------------|---------------|---------------|
|                        | 2001 | 2016 | APCR (95% CI) | Year | AP (95% CI) | Year | AP (95% CI) | Year | AP (95% CI) |
| CHD                    |      |      |              |      |            |      |            |      |            |
| All ages               | 477.3 | 146.0 | −76 (−10.2, −5.0)* | 2001−2003 | −231 (−38.8, −33)* | 2003−2016 | −50 (−6.0, −40)* |
| 20–44 years            | 155.9 | 55.1 | −73 (−15.0, 1.1) | 2001−2003 | −322 (−66.1, 35.7) | 2003−2016 | −2.7 (−6.0, 0.68) |
| 45–64 years            | 651.9 | 199.8 | −76 (−9.5, −5.7)* | 2001−2003 | −226 (−32.2, −11.7)* | 2003−2007 | −75 (−12.9, −19)* |
| 65–74 years            | 914.3 | 217.1 | −90 (−11.1, −6.8)* | 2001−2006 | −137 (−15.8, −11.5)* | 2006−2010 | −31 (−8.4, 2.6) |
| ≥ 75 years             | 813.3 | 281.1 | −65 (−8.7, −4.2)* | 2001−2006 | −93 (−13.7, −46)* | 2006−2010 | 36 (−4.5, 12.4) |
| Stroke                 |      |      |              |      |            |      |            |      |            |
| All ages               | 339.5 | 100.9 | −87 (−98, −7.5)* | 2001−2005 | −153 (−19.0, −11.3)* | 2005−2016 | −62 (−7.1, −5.2)* |
| 20–44 years            | 56.2  | 50.3  | −18 (−46, 1.1)  | 2001−2016 | −18 (−46, 1.1)  | 2001−2016 | −18 (−46, 1.1)  |
| 45–64 years            | 338.2 | 99.7  | −83 (−96, −7.1)* | 2001−2005 | −163 (−20.4, −120)* | 2005−2016 | −53 (−6.1, −44)* |
| 65–74 years            | 788.5 | 157.5 | −105 (−11.5, −9.9)* | 2001−2005 | −154 (−18.8, −120)* | 2005−2016 | −87 (−9.5, −7.9)* |
| ≥ 75 years             | 1224.8 | 289.0 | −96 (−10.6, −8.8)* | 2001−2005 | −148 (−18.3, −11.1)* | 2005−2016 | −76 (−8.3, −7.0)* |
| Heart failure          |      |      |              |      |            |      |            |      |            |
| All ages               | 228.6 | 83.1  | −64 (−8.0, −4.7)* | 2001−2005 | −128 (−18.3, −7.0)* | 2005−2016 | −39 (−5.2, −2.7)* |
| 20–44 years            | 41.6  | 30.8  | 1.2 (−24.4, 48) | 2001−2016 | 1.2 (−24.4, 48) | 2001−2016 | 1.2 (−24.4, 48) |
| 45–64 years            | 147.5 | 56.6  | −58 (−81, −3.5)* | 2001−2006 | −137 (−19.7, −7.3)* | 2006−2016 | −16 (−3.7, 0.52) |
| 65–74 years            | 431.9 | 116.4 | −85 (−10.0, −7.1)* | 2001−2009 | −113 (−13.3, −9.2)* | 2009−2016 | −53 (−7.8, −2.7)* |
| ≥ 75 years             | 1259.2 | 413.4 | −69 (−8.7, −5.1)* | 2001−2005 | −130 (−19.3, −62)* | 2005−2016 | −53 (−7.8, −2.7)* |
| Hyperglycaemic crisis  |      |      |              |      |            |      |            |      |            |
| All ages               | 81.5  | 33.3  | −66 (−12.4, −4.40)* | 2001−2003 | −300 (−57.9, 166) | 2003−2016 | −24 (−4.9, 0.24) |
| 20–44 years            | 151.7 | 66.0  | −39 (−62, −1.5)* | 2001−2016 | −39 (−62, −1.5)* | 2001−2016 | −39 (−62, −1.5)* |
| 45–64 years            | 25.4  | 10.1  | −70 (−10.6, −3.2)* | 2001−2005 | −223 (−33.0, −99)* | 2005−2016 | −7 (−3.5, 2.2) |
| 65–74 years            | 23.2  | 4.0   | −122 (−16.3, −7.9)* | 2001−2003 | −427 (−60.4, −17.2)* | 2003−2016 | −62 (−8.4, −4.0)* |
| ≥ 75 years             | 42.3  | 5.5   | −132 (−17.8, −8.9)* | 2001−2004 | −314 (−48.0, −9.5)* | 2004−2016 | −80 (−10.7, −5.3)* |
| LEA                    |      |      |              |      |            |      |            |      |            |
| All ages               | 36.0  | 11.7  | −58 (−7.2, −4.4)* | 2001−2016 | −58 (−7.2, −4.4)* | 2001−2016 | −58 (−7.2, −4.4)* |
| 20–44 years            | 14.1  | 3.8   | −74 (−19.5, 6.5)* | 2001−2006 | −87 (−22.4, 7.9) | 2006−2010 | 145 (−17.5, 590) |
| 45–64 years            | 37.5  | 18.4  | −28 (−47, −9.9)* | 2001−2016 | −28 (−47, −9.9)* | 2001−2016 | −28 (−47, −9.9)* |
| 65–74 years            | 28.0  | 16.4  | −80 (−95, −6.5)* | 2001−2016 | −80 (−95, −6.5)* | 2001−2016 | −80 (−95, −6.5)* |
| ≥ 75 years             | 123.0 | 16.6  | −105 (−12.1, −8.9)* | 2001−2016 | −105 (−12.1, −8.9)* | 2001−2016 | −105 (−12.1, −8.9)* |

CHD coronary heart disease, LEA lower-extremity amputation, APCR average annual percent change, AP annual percent change

*P < 0.05
| Complications | Event rates (per 10,000) | Time period 1 | Time period 2 | Time period 3 |
|---------------|--------------------------|---------------|---------------|---------------|
|               |                          | 2001–2005     | 2005–2010     | 2010–2016     |
|               |                          | 2005–2010     | 2010–2016     |               |
|               |                          | 2001–2016     |               |               |
| CHD           |                          |               |               |               |
| All ages      | 225.8                    | –9.9 (−11.8, −7.9)* | −16.3 (−20.0, −12.4)* | −32 (−8.4, 2.4)* |
| 20–44 years   | 18.6                     | −2.8 (−7.6, 2.3)  | −2.8 (−7.6, 2.3)  | −10.8 (−13.6, −7.9)* |
| 45–64 years   | 240.7                    | −10.9 (−12.1, −9.8)* | −19.6 (−23.2, −15.8)* | −7.6 (−8.6, −6.6)* |
| 65–74 years   | 623.5                    | −11.9 (−12.8, −10.9)* | −18.5 (−20.4, −16.5)* | −60 (−7.9, −4.3)* |
| ≥ 75 years    | 727.3                    | −7.7 (−8.7, −6.6)*  | −10.1 (−13.0, −7.1)* | −130 (−14.8, −11.2)* |
| Stroke        |                          |               |               |               |
| All ages      | 251.3                    | −9.0 (−9.6, −8.4)*  | −16.9 (−19.0, −14.8)* | −8.5 (−9.1, −7.9)* |
| 20–44 years   | 41.5                     | −4.4 (−7.5, −1.1)*  | −4.4 (−7.5, −1.1)*  | −5.5 (−6.8, −4.2)* |
| 45–64 years   | 216.1                    | −9.2 (−10.5, −8.0)* | −16.2 (−19.3, −12.9)* | −12.7 (−15.0, −9.1)* |
| 65–74 years   | 590.2                    | −11.5 (−13.0, −10.0)* | −19.2 (−25.7, −12.2)* | −16.4 (−19.2, −12.6)* |
| ≥ 75 years    | 1044.8                   | −9.4 (−10.7, −8.0)*  | −13.5 (−18.3, −8.4)* | −16.5 (−20.2, −19.9)* |
| Heart failure |                          |               |               |               |
| All ages      | 187.0                    | −7.0 (−8.0, −6.0)*  | −13.0 (−16.1, −9.8)* | −47 (−5.7, −3.8)* |
| 20–44 years   | 9.2                      | 3.4 (−24, 9.4)   | 3.4 (−24, 9.4)   | 4.4 (−6.3, 2.5)* |
| 45–64 years   | 87.4                     | −8.2 (−10.0, −6.2)* | −15.3 (−20.0, −10.3)* | −7.5 (−10.5, −4.4)* |
| 65–74 years   | 371.0                    | −9.8 (−11.2, −8.4)* | −15.7 (−20.3, −10.9)* | −7.6 (−8.8, −6.4)* |
| ≥ 75 years    | 1273.3                   | −5.9 (−6.8, −5.1)*  | −5.9 (−6.8, −5.1)* | −13 (−5.7, 3.4)* |
| Hyperglycaemic crisis |              |               |               |               |
| All ages      | 111.3                    | −8.5 (−10.5, −6.5)* | −8.5 (−10.5, −6.5)* | −18 (−10.5, −6.5)* |
| 20–44 years   | 225.1                    | −8.7 (−10.8, −6.6)* | −8.7 (−10.8, −6.6)* | −12.8 (−10.8, −6.6)* |
| 45–64 years   | 22.6                     | −5.9 (−9.1, −2.6)*  | −12.4 (−17.8, −6.7)* | −42 (−4.5, 5.1)* |
| 65–74 years   | 8.5                      | −7.5 (−10.5, −4.4)* | −7.5 (−10.5, −4.4)* | −57 (−10.8, −3.4)* |
| ≥ 75 years    | 48.7                     | −11.2 (−15.2, −6.9)* | −28.2 (−38.3, −18.4)* | −13 (−5.7, 3.4)* |
| LEA           |                          |               |               |               |
| All ages      | 21.6                     | −9.1 (−12.2, −5.8)* | −16.2 (−22.1, −9.9)* | −40 (−8.1, 0.32)* |
| 20–44 years   | 9.4                      | Not available | −15.5 (−32.5, 5.9) | −15.2 (−16.5, 18.9)* |
| 45–64 years   | 11.9                     | −6.4 (−10.0, −2.7)* | −15.0 (−23.7, −5.2)* | −18 (−5.5, 2.0)* |
| 65–74 years   | 39.2                     | −11.8 (−14.2, −9.4)* | −11.8 (−14.2, −9.4)* | −12.7 (−10.2)* |
| ≥ 75 years    | 102.2                    | −11.5 (−12.7, −10.2)* | −11.5 (−12.7, −10.2)* | −11.5 (−12.7, −10.2)* |

CHD coronary heart disease, LEA lower-extremity amputation, AAPC average annual percent change, APC annual percent change

* P < 0.05. As no women aged 20–44 years had amputation event in 2007, trend analysis was performed for 2001–2006 and 2008–2016, separately
40.2% in women in 2016. The increasing pattern was similar across all age groups but with a much lower prevalence in young people aged 20–44 years, which was 27.6% in men and 18.5% in women in 2016. New classes of glucose-lowering drugs including DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors were available in Hong Kong from 2007, 2011 and 2015, respectively. The prevalence of DPP-4 inhibitors use has increased to 7.8% in men and 6.4% in women in 2016 (Additional file 1: Table S6). However, the prevalence of GLP-1 receptor agonists and SGLT2 inhibitors use remained very low. In 2016, less than 0.2% of people with diabetes were prescribed GLP-1 receptor agonists, and about 0.8% of people were prescribed SGLT2 inhibitors.

**Discussion**

In this retrospective analysis of territory-wide data of Hong Kong Chinese aged 20 years and older with diabetes, we revealed substantial declines in event rates of five major diabetes-related complications including CHD, stroke, heart failure, hyperglycaemic crisis and LEA from 2001 to 2016. The declines were greater in the earlier part of the surveillance and diminished thereafter but no plateauing or increase in event rates was detected. The decrease in event rates of most complications were restricted to people aged 45 years and older. The younger group aged 20–44 years experienced decrease in rates of hyperglycaemic crisis but not in other complications.

Our findings provide important insights into the epidemiology of diabetes-related complications in Asia and indicate improvements in the quality of care of most people with diabetes in Hong Kong in recent years [21].

**Declining trends in diabetes-related complications**

Declines in rates of complications among people with diabetes have been reported in many western countries including the United Kingdom, Sweden and Canada up until the mid- to early 2000s [22]. Most recently, however, national statistics in the U.S. revealed increasing trends for several diabetes-related clinical events including acute myocardial infarction, stroke, LEA and hyperglycaemic crisis between 2010 and 2015, and the increase was the most apparent in the young and middle-aged people [23]. Comparable population-level statistics from Asian countries are limited [24–26]. A study in Taiwan showed an overall decline in hospitalization for diabetic ketoacidosis from 6.0 per 1000 person-years in 1997 to 5.0 in 2005 but with non-significant changes in young men and even rising trends in young women aged < 35 years [24]. In Korea, hospital admission rates fell by 29.5% for CHD and 37.3% for acute myocardial infarction among people with type 2 diabetes between 2006 and 2013 based on the National Health Insurance database [25].

Causes for the declines in event rates of diabetes-related complications in Hong Kong are likely to be multifactorial, including changes in clinical care, healthcare delivery system, socioeconomic environment, and individuals’ health-related behaviours. Between 1990s and the early millennium, in response to the rapidly growing burden of diabetes in Asia, a series of quality improvement programs were introduced in Hong Kong [21]. These include establishment of nurse-led diabetes centres in major public hospitals in 2000 to provide regular structured assessment of risk factors and complications to people with diabetes [27]. In 2007, the program was extended to all public primary care clinics as the diabetes Risk Assessment and Management Program (RAMP) to support clinical decision making and to promote patient adherence to self-care and medication [21, 28, 29]. These territory-wide changes in care organization along with advances in pharmacotherapy have resulted in better control of metabolic risk factors over the last two decades [27]. In 2007, the program was extended to all public primary care clinics as the diabetes Risk Assessment and Management Program (RAMP) to support clinical decision making and to promote patient adherence to self-care and medication [21, 28, 29]. These territory-wide changes in care organization along with advances in pharmacotherapy have resulted in better control of metabolic risk factors over the last two decades [27]. In the present study, we further detected a marked increase in the usage of statins which is likely to contribute to the improved outcomes during this time period given the proven cardiovascular benefits of statins [30].

Other contributing factors include health promotion campaigns and complementary policy changes aimed at reducing behavioural risk factors as evidenced by a stable trend in the prevalence of overweight or obesity and a decreased prevalence of cigarette smoking and physical
inactivity in Hong Kong [31, 32]. Positive changes in socioeconomic status of people with diabetes could also affect health outcomes through improvement in health literacy, disease awareness and lifestyles [33–35]. These societal and personal factors may bring about greater awareness leading to earlier detection and more timely intervention although we were unable to quantify the impacts of these factors on the trend estimates.

More marked declines in earlier part of the study period
The faster declines in rates of diabetes-related complications in the earlier than latter part of the study period concord with the more marked decrease in all-cause mortality among people with diabetes in the period between 2001 and 2006 than between 2006 and 2016 in Hong Kong [12]. The reason for the slowing down of improvement is not clear. One possible explanation could be that improved survival has resulted in increasing number of people with long diabetes duration and living to older ages who are at inherently higher risks of developing complications [36]. Long disease duration is a major determinant for diabetes-related complications although we do not have this data for analysis in this administrative database [27]. It is also conceivable that healthcare reforms beginning in the 1990s yielded the greatest benefits during the period around its inception which then lessen over time.

Unchanged rates of vascular complications in young people with diabetes
In clinic-based population, one in five adults with type 2 diabetes in Asia are diagnosed before the age of 40 years [37]. Contrary to a stabilizing trend of incidence of diabetes in the older age group, incidence of young-onset diabetes has continued to increase in Hong Kong. In a multinational study in Asia, people with young-onset diabetes had more adverse metabolic profiles and were less likely to achieve treatment goals and to receive organ-protective drugs such as statins and renin-angiotensin system inhibitors than those with late-onset diabetes [37]. In the present study, 18% of women and 27% of men in the 20–44 age group were prescribed statins compared to over 50% in other age groups. In our previous analysis on mortality rate during the same period, improvements in HbA1c and LDL-cholesterol levels in young people were smaller than their older counterparts [12]. This was reflected by the lack of reduction in all-cause mortality in young people who had fivefold higher risk of mortality compared with age-matched people without diabetes. In a separate study, we estimated that people with young-onset diabetes spent an average of 97 days in hospital up to the age of 75 years, which are substantially reduced by 30% if all risk factors are optimized and by 70% if the onset of diabetes can be delayed to after the age of 65 years [38].

Changes in contribution of different age groups to diabetes-related complications
We observed a significant shift in contribution to most cardiovascular diseases including coronary heart disease, stroke and heart failure from people aged 65–74 years to the oldest group aged ≥ 75 years. This differed from the U.S. population in whom the proportion of diabetes-related complications increased in people aged 45–64 years but decreased in older people aged ≥ 65 years [39]. The results in our study might reflect a combined effect of increased proportion of the oldest people aged ≥ 75 years living with diabetes in Hong Kong and a delay in onset of complications. This observation has important implications for utilization of health services given the large and continually increasing number of older people with diabetes in Hong Kong and the profound economic burden of diabetes and its complications. For LEA, middle-aged adults (45–64 years) accounted for a greater proportion of LEA events in 2016 compared to 2001, although the event rate has declined. The reasons are unclear but may reflect a number of factors including patients’ preference for earlier amputations to prevent more serious functional loss, improved health resources with earlier referral, and changes in doctors’ attitude of whether to amputate. Further studies are needed to clarify this.

Strengths and limitations
The major strengths of this study include the territory-wide coverage with minimal selection bias, and a long surveillance period. There are several limitations of this study. Firstly, our findings were restricted to people attending hospitals and clinics in the public sector. However, given the heavily subsidized public healthcare system, the HA provides over 90% of the inpatient services in Hong Kong [27]. The exclusion of the very small proportion of people who presented to the private sector should have little effect on the overall trend estimates and is unlikely to have seriously biased our conclusions. Secondly, due to the lack of information on people’s medical records before 2000, we were not able to distinguish between the first incident and recurrent events. As a result, we were unable to ascertain whether the declines in event rates of diabetes-related complications were due to decreasing number of people with new-onset events or due to people having fewer recurrent events. Thirdly, as information on secondary diagnosis codes was not available, major events that have occurred but listed as secondary diagnoses were not included in our study leading to potential underestimation of events. Fourthly, a trend in
earlier detection of diabetes through diagnostic improvement and screening approaches might have produced a lead time bias. More people with screen-detected diabetes contributed to the denominator in recent compared to earlier years, and a temporal decline in event rate of complications could be detected even if the event has occurred at the same time point along the disease trajectory without being delayed. However, exclusion of people with newly diagnosed diabetes in each year did not affect the trends in rates of diabetes-related complications. Fifthly, the HKDSD is derived from an administrative source with a potential limitation in validity. We could not rule out the possibility of including people who used glucose-lowering drugs for reasons other than diabetes such as prediabetes and polycystic ovarian syndrome, although the number is deemed small. Additionally, we were not able to differentiate between the types of diabetes in people with diabetes onset before 2002. In our sensitivity analysis, removal of people with type 1 diabetes of onset between 2002 and 2015 as identified using a validated algorithm did not affect the trend estimates [40]. Lastly, we did not include all diabetes-related complications in our study. Future studies are needed to explore the trends of other important diabetes-related complications such as end stage kidney disease and severe retinopathy.

Conclusions
Using surveillance data, we reported significant declines in event rates of major diabetes-related complications among people with diabetes in Hong Kong, but not in young adults, highlighting the importance of improving quality of care to prevent complications in young people at risk. Although the event rates have fallen, the absolute number of events has not decreased, and there were progressive increases in the contribution to most diabetes-related complications from the oldest age group. Given the increasing life expectancy of people with diabetes and the vulnerability of older individuals to cardiovascular diseases, healthcare resources should be appropriately prioritized to support management of these complications to reduce disability and maximise quality of life.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12933-020-01039-y.

Additional file 1: Figure S1. Number of men and women with diabetes in the middle of the year by age in Hong Kong between 2001 and 2016. Figure S2. Number of events of diabetes-related complications in men and women with diabetes in Hong Kong between 2001 and 2016. Figure S3. Age-standardized event rates of diabetes-related complications in men and women with diabetes in Hong Kong between 2001 and 2016. Figure S4. Proportion of coronary heart disease events by age group in men and women with diabetes in Hong Kong between 2001 and 2016. Figure S5. Proportion of stroke events by age group in men and women with diabetes in Hong Kong between 2001 and 2016. Figure S6. Proportion of heart failure events by age group in men and women with diabetes in Hong Kong between 2001 and 2016. Figure S7. Proportion of hyperglycaemic crisis events by age group in men and women with diabetes in Hong Kong between 2001 and 2016. Figure S8. Proportion of amputation events by age group in men and women with diabetes in Hong Kong between 2001 and 2016. Table S1. Characteristics of people in the HKDSD between 2001 and 2016. Table S2. Age-standardized event rates (per 10,000) of diabetes-related complications in men with diabetes by age in Hong Kong between 2001 and 2016. Table S3. Age-standardized event rates (per 10,000) of diabetes-related complications in women with diabetes by age in Hong Kong between 2001 and 2016. Table S4. Joinpoint analysis of trends in age-standardized event rates of minor and major LEA in men and women with diabetes in Hong Kong between 2001 and 2016. Table S5. Age-standardized prevalence (%) of statin use in people with diabetes by sex and age in Hong Kong between 2001 and 2016. Table S6. Age-standardized prevalence (%) of DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors use in people with diabetes by sex and age in Hong Kong between 2001 and 2016.

Abbreviations
AAPC: Average annual percent change; APC: Annual percent change; CHD: Coronary heart disease; DPP-4: Dipeptidyl-peptidase-4; EMR: Electronic medical record; GLP-1: Glucagon-like peptide-1; HA: Hospital Authority; HbA1c: Glycated haemoglobin; HKDSD: Hong Kong Diabetes Surveillance Database; ICD-9: International Classification of Diseases Ninth Revision; LDL: Low-density lipoprotein; LEA: Lower-extremity amputation; RAMP: Risk Assessment and Management Program; SGLT-2: Sodium-glucose co-transporter-2; U.S.: United States.

Acknowledgements
We acknowledge the Hong Kong Hospital Authority for providing access to the electronic medical record.

Authors’ contributions
HW contributed to conception of the article, statistical analysis, results interpretation, drafted the manuscript, revised the manuscript critically and approved the final version. AOYL and JCNC contributed to conception of the article, results interpretation, revised the manuscript critically and approved the final version. ESHL contributed to conception of the article, results interpretation, revised the manuscript critically and approved the final version. YL, RCWM, APSL, EC, and WYS contributed to conception of the article, revised the manuscript critically and approved the final version. AOYL is the guarantor of this work, has full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Funding
HW is partially supported by a research grant from the Asia Diabetes Foundation.

Availability of data and materials
The datasets used during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
This study was approved by the local clinical research ethics committee at the Chinese University of Hong Kong.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.
Author details
1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region, People's Republic of China. 2 Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region, People's Republic of China. 3 Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong Special Administrative Region, People's Republic of China. 4 Hong Kong Hospital Authority, Kowloon, Hong Kong Special Administrative Region, People's Republic of China.

Received: 18 February 2020 Accepted: 9 May 2020
Published online: 12 May 2020

References
1. International Diabetes Federation. IDF Diabetes Atlas. 9th ed. Brussels: International Diabetes Federation, 2019.

2. Fowler MJ, Micovacic S, and macrovascular complications of diabetes. Clin Diabetes. 2008;26(2):77–82.

3. Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetes. 2018;17(1):92.

4. Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova D, Woerle HJ. Empagliflozin, cardiovascular outcomes in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetes. 2018;17(1):150.

5. Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.

6. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.

7. Davies MJ, DAlessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rosing P, Trappas A, Wexler DJ, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabete (EASD). Diabetologia. 2018;61(12):2461–98.

8. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K, Hu FB. Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.

9. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.

10. Wu H, Feng Y, Hong L, Huo J, Li J, Wang J, et al. Cardiovascular outcomes in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetes. 2018;17(1):150.

11. Chan JCN, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K, Hu FB. Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.

12. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.

13. Davies MJ, DAlessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rosing P, Trappas A, Wexler DJ, Buse JB. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabete (EASD). Diabetologia. 2018;61(12):2461–98.

14. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K, Hu FB. Diabetes Control Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86.

15. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.

16. American Diabetes Association. 10 Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement 1):S103–23.

17. Hsu C-Y, Chen Y-T, Su Y-W, Chang C-C, Huang P-H, Lin S-J. Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab. 2017;102(7):2373–81.

18. Pantalone KM, Misra-Hebert AD, Hobbs TM, Ji X, Kong SX, Milinovich A, Weng W, Bauman J, Ganguly R, Burguera B. Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. Cardiovasc Diabetes. 2018;17(1):54.

19. Fei Y, Toi M-F, Cheung BMY. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis. Cardiovasc Diabetes. 2019;18(1):112.

20. Ke C, Stukel TA, Luk A, Shah BR, Jha P, Lau E, Ma RC, So W-Y, Kong AP, Chow E. Development and validation of algorithms to classify type 1 and 2 diabetes according to age at diagnosis using electronic health records. BMC Med Res Methodol. 2020;20(1):1–15.

21. Chan JCN, Lim L-L, Luk AOY, Ozaki R, Kong APS, Ma RCW, So W-Y, Lo S-V. From Hong Kong Diabetes Register to JADE Program to RAMP-DM for data-driven actions. Diabetes Care. 2019;42(11):2022–31.

22. Harding JL, Pavkovic ME, Magliano DJ, Shaw JE, Gregg EW. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019;62(8):1420–9.

23. Gregg EW, Hora J, Benoist SR. Resurgence in Diabetes-Related Complications. JAMA. 2019;321(19):1867–8.

24. Liu C-C, Chen K-R, Huang H-L, Ko M-C, Li C-Y. Trends in Asian-specific diabetes mortality in Taiwan from 1997–2005. J Formos Med Assoc. 2010;109(10):725–34.

25. Jung CH, Chung JO, Han K, Ko S-H, Ko KS, Park J-Y. Improved trends in cardiovascular complications among subjects with type 2 diabetes in Korea: a nationwide study (2006–2013). Cardiovasc Diabetes. 2017;16(1):1.

26. Kaewput W, Thongprayoon C, Munthin M, Jindarat S, Varothai N, Suwannatattorn P, Rangsin R, Mao MA, Cheungpasitporn W. Temporal trends in optimal diabetic care and complications of elderly type 2 diabetes patients in Thailand: a nationwide study. J Evol Med Based. 2019;12(1):1–22.

27. Liu AO, Hui EM, Sin M, Yeung C, Chow W, Hung H, Kan E, Ng C, So W. Declining trends of cardiovascular-renal complications and mortality in type 2 diabetes: the Hong Kong Diabetes Database. Diabetes Care. 2017;40(7):928–35.

28. Wan EYF, Fung CSC, Jiao FF, Yu EYT, Chin WY, Fong DYT, Wong CKH, Chan AKC, CHY, Kwok R, Liu AKC. Five-year effectiveness of the multidisciplinary Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) on diabetes-related complications and health service use—a population-based and propensity-matched cohort study. Diabetes Care. 2018;41(1):49–59.

29. Ko GT, So W, Tong PC, Le Gogueur F, Kerr D, Lyubomirsky G, Tamesis B, Wolthers T, N, Chan JCN, et al. From design to implementation-The Joint Asia Diabetes Evaluation (JADE) program: a descriptive report of an electronic web-based diabetes management program. BMC Med Inform Decis Mak. 2010;10(1):26.

30. Collaboration Cholesterol Treatment Trialsist's Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397–405.

31. Statistics on behavioural risk factors. https://www.chp.gov.hk/en/statistics. Accessed 4 June 2019.

32. Pattern of smoking in Hong Kong. https://www.taco.gov.hk/v/english/infostation/infostation_sta_01.html. Accessed 4 June 2019.

33. Ravshani A, Svensson A-M, Zethelius B, Eliasson B, Rosen gren A, Gudbjörnsdottir S. Association between socioeconomic status and mortality, cardiovascular disease, and cancer in patients with type 2 diabetes. JAMA Intern Med. 2016;176(8):1146–54.

34. Wu H, Bragg F, Yang L, Du H, Guo Y, Jackson CA, Zhu S, Yu C, Luk AOY, Chan JCN, et al. Sex differences in the association between socioeconomic status and diabetes prevalence and incidence in China: cross-sectional and prospective studies of 0.5 million adults. Diabetologia. 2019;62(8):1420–9.
35. Wu H, Lau ES, Kong AP, Ma RC, Ozaki R, Cheung KK, Chow E, Tsang CC, Lau KP, Hui EM, et al. Association between educational level and cardiovascular disease and all-cause mortality in patients with type 2 diabetes: a prospective study in the Joint Asia Diabetes Evaluation Program. Clin Epidemiol. 2018;10:1561–71.

36. Li Y, Zou Y, Wang S, Li J, Jing X, Yang M, Wang L, Cao L, Yang X, Xu L. A pilot study of the FRAIL scale on predicting outcomes in Chinese elderly people with type 2 diabetes. J Am Med Dir Assoc. 2015;16(8):714.

37. Yeung RO, Zhang Y, Luk A, Yang W, Sobrepena L, Yoon K-H, Aravind S, Shue W, Nguyen TK, Ozaki R. Metabolic profiles and treatment gaps in young-onset type 2 diabetes in Asia (the JADE programme): a cross-sectional study of a prospective cohort. Lancet Diabetes Endocrinol. 2014;2(12):935–43.

38. Ke C, Lau E, Shah BR, Stukel TA, Ma RC, So W-Y, Kong AP, Chow E, Clarke P, Goggins W. Excess burden of mental illness and hospitalization in young-onset type 2 diabetes: a population-based cohort study. Ann Intern Med. 2019;170(3):145–54.

39. Gregg EW, Li Y, Wang J, Rios Burrows N, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370(16):1514–23.

40. Luk AOY, Ke C, Lau ESH, Wu H, Goggins W, Ma RCW, Chow E, Kong APS, So W-Y, Chan IJN. Secular trends in incidence of type 1 and type 2 diabetes in Hong Kong: a retrospective cohort study. Plos Med. 2020;17(2):e1003052.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.